India’s Cipla calls for revocation of Novartis’ Onbrez patents
Indian drugmaker Cipla (BSE: 500087) has asked the government to revoke five patents that Swiss pharma major Novartis (NOVN: VX) holds on its chronic obstructive pulmonary disease (COPD) drug Onbrez (indacaterol), according to the Economic Times of India and other media reports.
Meantime, Cipla launched its generic version of indacaterol - under the Unibrez trade name - at a fifth of the price, triggering another confrontation between an Indian generic company and a foreign innovator firm. The domestic drugmaker asked the Department of Industrial Policy and Promotion (DIPP) to cancel the patents on the ground that the Swiss company has held them for six years without making the medicine locally or importing it in the quantity that's required.
Onbrez price 400% more than that Cipla charges for its indacaterol
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze